Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jeffrey Gary Schneider
Observed names:
J G Schneider,
J Schneider,
J. G. Schneider,
J. Schneider,
J.G. Schneider,
JEFFREY G SCHNEIDER,
JEFFREY SCHNEIDER,
Jeffrey G Schneider,
Jeffrey G. Schneider,
Jeffrey Schneider
show all 10
Observed institutions:
Winthrop-University Hospital,
State University of New York,
Memorial Sloan Kettering Cancer Center,
NewYork–Presbyterian Hospital,
NYU Langone Health,
NYU Grossman Long Island School of Medicine,
New York University,
Stony Brook University
show all 8
OpenAlex ID:
A5067734724
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019
·
Luis Paz-Ares
, Mikhail Dvorkin
, et al.
·
The Lancet
·
2,281
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020
·
Jonathan W Goldman
, Mikhail Dvorkin
, et al.
·
The Lancet Oncology
·
688
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
2020
·
Naiyer A. Rizvi
, Byoung Chul Cho
, et al.
·
JAMA Oncology
·
622
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
2018
·
Neal Ready
, Anna F. Farago
, et al.
·
Journal of Thoracic Oncology
·
344
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
2018
·
G.V. Long
, S.S. Tykodi
, et al.
·
Annals of Oncology
·
206
PDF
Interactions among colony-stimulating factors, IL-1 beta, IL-6, and kit-ligand in the regulation of primitive murine hematopoietic cells.
1992
·
M O Muench
, J G Schneider
, et al.
·
PubMed
·
100
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
2021
·
Mila B. Ortigoza
, Hyunah Yoon
, et al.
·
JAMA Internal Medicine
·
87
PDF
Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer.
1993
·
J Crown
, A Kritz
, et al.
·
Journal of Clinical Oncology
·
70
Treatment of Resistant Gestational Choriocarcinoma with Taxol: A Report of Two Cases
1996
·
Walter B. Jones
, Jeffrey Schneider
, et al.
·
Gynecologic Oncology
·
62
Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor a randomized trial
1993
·
Alan Kritz
, John P. Crown
, et al.
·
Cancer
·
52
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)
2020
·
David Spigel
, Robert Jotte
, et al.
·
Journal of Thoracic Oncology
·
49
PDF
Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.
1995
·
D Fennelly
, J Schneider
, et al.
·
Journal of Clinical Oncology
·
43
A Retrospective Review of CyberKnife Stereotactic Body Radiotherapy for Adrenal Tumors (Primary and Metastatic): Winthrop University Hospital Experience
2015
·
Amishi Desai
, Hema Rai
, et al.
·
Frontiers in Oncology
·
39
PDF
Rapid Delivery of Multiple High-Dose Chemotherapy Courses With Granulocyte Colony-Stimulating Factor and Peripheral Blood-Derived Hematopoietic Progenitor Cells
1992
·
JOHN CROWN
, CAROLYN WASSHERHEIT
, et al.
·
JNCI Journal of the National Cancer Institute
·
36
Intraperitoneal Chemotherapy
1994
·
Jeffrey G. Schneider
·
Obstetrics and Gynecology Clinics of North America
·
32
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC)
2021
·
Edward B. Garon
, Byoung Chul Cho
, et al.
·
Clinical Lung Cancer
·
28
PDF
High-Intensity Intravenous Cyclophosphamide and Cisplatin, Interim Surgical Debulking, and Intraperitoneal Cisplatin in Advanced Ovarian Carcinoma: A Pilot Trial with Ten-Year Follow-up
1997
·
Fred Shapiro
, Jeffrey Schneider
, et al.
·
Gynecologic Oncology
·
27
MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial
2017
·
Matthew Hellmann
, Scott Antonia
, et al.
·
Journal of Thoracic Oncology
·
22
PDF
Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
1994
·
J G Schneider
, J P Crown
, et al.
·
PubMed
·
19
Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?
2012
·
Jeffrey G. Schneider
, Danny N. Khalil
·
Breast Cancer Research and Treatment
·
17
Treatment of Malignancy by Activation of the Plasminogen System
2002
·
Leo R. Zacharski
, Deborah L. Ornstein
, et al.
·
Seminars in Thrombosis and Hemostasis
·
13
Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study
2019
·
N. Reinmuth
, B.C. Cho
, et al.
·
Annals of Oncology
·
10
PDF
Commercial Laboratory Testing of Excision Repair Cross-Complementation Group 1 Expression in Non-Small Cell Lung Cancer
2014
·
Jeffrey G. Schneider
, Nosha Farhadfar
, et al.
·
The Oncologist
·
10
Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Small Academic Hospital Experience
2014
·
Oren B. Factor
, Charles C. Vu
, et al.
·
Frontiers in Oncology
·
9
PDF
High-intensity chemotherapy with peripheral blood progenitor cell support.
1994
·
D Fennelly
, L Vahdat
, et al.
·
PubMed
·
9
Show more works
View as search
Works count:
49
Citation count:
4,898
H-index:
19
I10-index:
23
Year
Topic
Type
